SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Manuela Valente submitted a Form 144 reporting proposed sales of Common Stock and an offer of Restricted Stock Units. The filing lists an offer of 380 Restricted Stock Units dated 05/18/2026 and multiple 10b5-1 sale transactions dated in 03/19/2026 through 04/20/2026.
SOPH affiliate submitted a Form 144 reporting proposed and recent sales of Common Stock under Rule 144 and 10b5-1 transactions. The filing lists restricted stock unit grants of 608 shares (05/18/2026) and 15,000 RSUs (04/02/2025). It also itemizes multiple 10b5-1 sales by Philippe Menu, including 5,000-share trades on 05/12/2026 and other dates with dollar proceeds shown per trade.
Rule 144 notice relates to the proposed sale of 761 restricted stock units reported with a trade date of 05/18/2026 and a filing line dated 05/19/2026. The filing lists multiple prior 10b5-1 sales by Ross J Muken between 03/19/2026 and 04/20/2026, including transactions of 4,442 shares on 04/13/2026 ($21,166.13).
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of 684 shares represented by Restricted Stock Units dated 05/18/2026. The filing also lists multiple 10b5-1 sales by Daan Guido Maria Van Well totaling several transactions in March–April 2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice documenting planned and recent dispositions of Common Stock linked to Restricted Stock Units. The filing lists an intended sale of 4,608 shares of Common Stock from Restricted Stock Units dated 05/18/2026. It also itemizes multiple 10b5-1 sales by the holder between 03/13/2026 and 05/13/2026, including transactions of 4,000 and 4,414 shares on individual dates. The cover data shows 68,486,338 shares referenced alongside the filing date 05/19/2026.
SOPHiA GENETICS SA filed a Form 6-K noting that it has published its 2025 Environmental, Social and Governance (ESG) Impact Summary as of December 31, 2025. The summary is made available on the company’s website in the Investor Relations section.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.5421 per share. The sale was executed under a pre-established Rule 10b5-1(c) trading plan, and Xu held 626,888 shares directly after the transaction.
SOPHiA GENETICS SA director Kathy L. Hibbs reported an open-market sale of 7,508 Ordinary Shares on May 12, 2026. The shares were sold at a weighted average price of $4.6666 per share, in multiple trades between $4.54 and $4.85.
The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Hibbs directly owns 89,768 Ordinary Shares. This represents a partial reduction of her holdings while retaining a substantial remaining position in the company.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on May 12, 2026 at a weighted average price of $4.6689 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan, and Menu now holds 256,388 shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 ordinary shares in an open-market transaction. The sale took place at a weighted average price of $5.0872 per share under a duly adopted Rule 10b5-1(c) trading plan. Following this transaction, he reports direct ownership of 3,633,981 ordinary shares.